Solventum (NYSE:SOLV – Get Free Report) and Avinger (NASDAQ:AVGR – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
Earnings and Valuation
This table compares Solventum and Avinger”s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Solventum | N/A | N/A | N/A | N/A | N/A |
Avinger | $7.43 million | 0.21 | -$18.32 million | ($18.19) | -0.05 |
Solventum has higher earnings, but lower revenue than Avinger.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Solventum | N/A | N/A | N/A |
Avinger | -260.86% | N/A | -117.86% |
Insider and Institutional Ownership
18.3% of Avinger shares are held by institutional investors. 11.4% of Avinger shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations for Solventum and Avinger, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Solventum | 1 | 8 | 1 | 0 | 2.00 |
Avinger | 0 | 0 | 1 | 0 | 3.00 |
Solventum currently has a consensus target price of $64.33, suggesting a potential downside of 11.40%. Avinger has a consensus target price of $5.00, suggesting a potential upside of 456.79%. Given Avinger’s stronger consensus rating and higher possible upside, analysts plainly believe Avinger is more favorable than Solventum.
Summary
Avinger beats Solventum on 5 of the 7 factors compared between the two stocks.
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
About Avinger
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.